Physician profile
David L Brown
NPI 1194717348
$20,431.13
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,741 · 2021: $50.12 · 2022: $261 · 2023: $270 · 2024: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $15,301.39 | 2019-2023 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $4,729.60 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $127.14 | 2022 | |
| Harrow Eye, LLC | $100.14 | 2024 | Iheezo |
| Novartis Pharmaceuticals Corporation | $37.53 | 2021 | |
| Tactile Systems Technology INC | $32.59 | 2022 | |
| Boston Scientific Corporation | $29.40 | 2019-2021 | |
| Abbott Laboratories | $19.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.59 | 2020 | |
| Amgen INC. | $13.59 | 2019 | |
| Ge Healthcare | $13.18 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.11 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,499,688.97 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.